P53、RasP21、C—erbB_2癌基因产物在横纹肌肉瘤的表达和预后

The Expressions and Prognosis of P53,P21 and P185 Oncogene Products in Rhabdomyosarcoma

用Ｐ５３及Ｒａｓ、Ｃ—ｅｒｂＢ２癌基因产物Ｐ２１、Ｐ１８５，通过免疫组化法，对确诊并随访的４１例横纹肌肉瘤（ＲＭＳ）进行检测。结果发现Ｐ５３、Ｐ２１、Ｐ１８５在ＲＭＳ的阳性表达率分别为７５．６１％、６５．８５％及６５．８５％，而在不同分化的ＲＭＳ中，Ｐ５３、Ｐ２１在低分化（Ⅲ级）的阳性率为８７．５％及７５．０％，与高分化（Ⅰ级）相比，差异有显著性（Ｐ＜０．０５）。但三种癌基因的阳性表达与其组织学分类无关（Ｐ＞０．０５）。Ｐ５３、Ｐ２１在ＲＭＳ的阳性率越高，阳性强度越强，其存活期越短。本组２年存活期２０例中，其Ｐ５３、Ｐ２１的阳性率８０％及７０％，且强度为＋＋～＋＋＋，而７例５年存活期的阳性率为４．８７％及２．４３％。且强度为－～＋（Ｐ＜０．０５）。上述结果提示Ｐ５３、Ｐ２１，尤其前者可作为估计ＲＭＳ预后的重要指标。

Forty-one cases of rhabdomyosarcoma (RMS),which had been confirmed and followed up,were examinated with immunohistochemistry staining to observe the expressions of P53,P21 and P185 oncogene products. The positive expressions of P53, P21 and P185 in RMSwere 75. 61 %, 65. 85% and 65. 85% respectively. In different histological types of RMS,the positive rates of P53 and P21 in poor RMS were 87. 5% and 75. 0% and compaired with high RMS, the difference was significant (P<0. 05). But there was no relationship between the positive expressions and the histological types (P>0. 05). The higher the positive rates of P53 and P21,the stronger their tenses,then the shorter its survival time. In 20 cases of twoyear survival, the positive rates of P53 and P21 were 80% and 70%,and their tenses were ++～+++. On the orber hand,in 7 cases of five-year survival,the positive rate were 4. 87 %and 2. 4 % and their tenses were-～+ (P<0. 05). The results suggest that P53 and P21, especially the former,can be one important sign in estimating prognosis in ARMS.